Natera

Natera, founded in 2004, is a global leader in cell-free DNA (cfDNA) testing, specializing in oncology, women's health, and organ health. The company leverages proprietary next-generation sequencing and advanced software platforms to provide clinical diagnostics that support personalized medical interventions and standard-of-care improvements. Meet Natera's team to understand the scientific expertise and leadership driving these molecular diagnostic advancements across their global research and development initiatives.

Operating with 5,000-10,000 employees across 7 locations, Natera maintains a robust infrastructure for laboratory services, system integration, and clinical commercialization. The company’s diverse product portfolio includes the Panorama non-invasive prenatal test, Horizon carrier screening, and the Prospera organ transplant monitoring test, all supported by a proprietary data analysis system. Learn about Natera's global headquarters for detailed information regarding their operational footprint in Austin, Texas, and their broader international presence in North America and beyond.

As a publicly traded entity on the NASDAQ under the ticker NTRA, Natera demonstrates significant market scale with annual revenue reaching $2.5B. The company competes with major diagnostic firms such as Illumina, Exact Sciences, and Quest Diagnostics, maintaining a strong position through continuous innovation in genetic testing technology and laboratory services. Explore financial highlights to review the company's fiscal performance, extensive funding history, and growth metrics within the highly competitive molecular diagnostics sector, reflecting their ongoing commitment to clinical excellence and patient-focused diagnostic solutions.